Triple Antibiotic Therapy for Maggot-Infested Wounds
For maggot-infested wounds, use the "Triple Therapy" regimen: oral ivermectin 12 mg daily for 3 days, albendazole 400 mg twice daily for 3 days, and clindamycin 300 mg three times daily for 5 days. This systemic approach achieves rapid larval clearance (>90% reduction by day 3) and addresses the polymicrobial bacterial infection that accompanies myiasis 1.
Rationale for Triple Therapy
The combination targets both the parasitic infestation and secondary bacterial infection:
- Ivermectin: Antiparasitic agent that paralyzes and kills fly larvae through GABA receptor activation
- Albendazole: Broad-spectrum anthelmintic providing additional antiparasitic coverage
- Clindamycin: Covers gram-positive organisms (staphylococci, streptococci) and anaerobes commonly found in contaminated wounds
Evidence Base
A prospective observational study of 25 patients with malignant wound myiasis demonstrated that this triple therapy regimen achieved:
- 73% reduction in maggot burden by day 1
- 92.6% reduction by day 3
- Significant improvement in pain, odor, and wound appearance
- Minimal, self-limiting side effects 1
This approach is particularly valuable for advanced head and neck cancer patients with malignant fungating wounds, where myiasis represents a devastating complication 2.
Adjunctive Wound Management
While systemic triple therapy forms the cornerstone, combine with:
- Mechanical removal: Manual extraction of visible larvae
- Topical agents: Turpentine oil dressing has been used safely in the Indian literature 1
- Pain control: Oral morphine titrated to effect (mean dose ~100 mg in the study cohort)
- Tetanus prophylaxis: Tdap if not vaccinated within 10 years 3
Important Distinctions
Do not confuse pathologic myiasis with therapeutic larval debridement therapy. Sterile Lucilia sericata larvae used in controlled medical settings provide selective debridement and are fundamentally different from spontaneous infestation by Chrysomyia bezziana or Cochliomyia hominivorax in neglected wounds 2, 4.
Coverage Considerations from IDSA Guidelines
While the IDSA guidelines 3 do not specifically address myiasis, they provide relevant guidance for contaminated wounds requiring polymicrobial coverage. The clindamycin component of triple therapy aligns with IDSA recommendations for anaerobic coverage (600 mg IV every 6-8 hours for severe infections, or 300 mg PO three times daily for moderate infections).
The triple therapy regimen specifically addresses the unique pathophysiology of myiasis—combining antiparasitic action with antibacterial coverage—making it superior to standard wound infection regimens alone.